Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.…
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
Aquestive Therapeutics (NASDAQ: AQST) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 147 employees.
The shares were at 3.460 USD on 20 November 2026, down 42.3% over 52 weeks. Its 52-week range is 2.930 USD to 6.850 USD: the price is 49.5% below the high and 18.1% above the low.
Its market capitalisation is 434.88M USD.
Aquestive Therapeutics reports return on equity of 248.9%, an operating margin of -114.1% and revenue down 41.0% year over year.
It holds more cash than debt, a net cash position of 31.58M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.333 USD is 169.7% above the current price. The next earnings report is expected on 3 March 2027.